KYNB.US Kyntra Bio, Inc.
- Market cap
- USD 13.9M
- P/E
- -
- P/B
- 80.40x
- ROE
- -
- Dividend yield
- 28.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is KYNB.US undervalued?
Graham numberThe Graham number of Kyntra Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyntra Bio, Inc. fundamental analysis
No fundamental analysis for Kyntra Bio, Inc. yet.
Kyntra Bio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical developme…
Full company profileKyntra Bio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyntra Bio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 180M | 126M | 213M | 257M | 176M | 235M | 141M | 46.8M | 29.6M | 6.44M | 4.53M |
| Gross Profit | -7.63M | -70.8M | -22.9M | 255M | 167M | -214M | 120M | 42.8M | 14.1M | 5.88M | -3.69M |
| Operating Income | -53.7M | -123M | -86.7M | -89.3M | -192M | -289M | -301M | -323M | -150M | -45.9M | -62.8M |
| EBITDA | -45.0M | -105M | -68.6M | -52.3M | -164M | -334M | -283M | -305M | -142M | -57.5M | -124M |
| Net Income | -61.7M | -126M | -86.4M | -77.0M | -189M | -290M | -294M | -284M | -47.6M | 183M | -6.45M |
| EPS | -25 | -43 | -26 | -22 | -53 | -79 | -78 | -73 | -12 | 45 | -1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 470M | 899M | 881M | 857M | 827M | 774M | 610M | 424M | 215M | 120M | 101M |
| Total Liabilities | 294M | 316M | 352M | 322M | 385M | 545M | 612M | 586M | 398M | 115M | 109M |
| Shareholders' Equity | 156M | 563M | 509M | 516M | 422M | 209M | -21.4M | -204M | -226M | -30.0M | -30.1M |
| Cash & Short-term Investments | 253M | 736M | 621M | 534M | 687M | 405M | 422M | 236M | 50.5M | 89.0M | 91.3M |
| Total Debt | 97.4M | 97.8M | 97.2M | 51.9M | 39.8M | 99.7M | 89.9M | 170M | 73.1M | 85.5M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.11M | -66.5M | -76.1M | -78.7M | 81.6M | -82.2M | -146M | -315M | -138M | -4.77M | -35.8M |
| Capital Expenditure | 1.25M | 8.50M | 8.02M | 5.76M | 3.99M | 30.2M | 38.7M | 2.52M | 266K | 38.0K | 0.00 |
| Free Cash Flow | 5.86M | -75.0M | -84.2M | -84.5M | 77.6M | -112M | -185M | -318M | -138M | -4.81M | -35.8M |
| Ratios | |||||||||||
| ROE | -39.6% | -22.4% | -17.0% | -14.9% | -44.8% | -138.7% | - | - | - | - | - |
| ROA | -13.1% | -14.0% | -9.8% | -9.0% | -22.9% | -37.5% | -48.1% | -67.1% | -22.2% | 153.4% | -6.4% |
| Net Profit Margin | -34.3% | -100.4% | -40.6% | -30.0% | -107.4% | -123.3% | -208.7% | -607.3% | -160.6% | 2,848.6% | -142.4% |
| Debt to Equity | 0.62x | 0.17x | 0.19x | 0.10x | 0.09x | 0.48x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyntra Bio, Inc. dividends
- Dividend yield
- 28.34%
- Forward dividend
- -
- Payout ratio
- 2.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 3.95M | 0.98 | 2.2% |
| 2024 | USD 2.23M | 0.56 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Jun 17, 2025.
Who owns Kyntra Bio, Inc.
- Insiders 2.21%
- Institutions 24.58%
- Public & others 73.21%
- Shares outstanding 4.05M
- Free float 3.57M
Top funds holding KYNB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 114K | 2.82% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 17.5K | 0.43% | -7.29% | Sep 2026 |
| Fidelity Total Market Index | 7.01K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 5.74K | 0.14% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 3.51K | 0.09% | 0.00% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 2.72K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.99K | 0.05% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.42K | 0.04% | 0.00% | Sep 2026 |
| Knights of Columbus U.S. All Cap Idx I | 23.00 | 0.00% | +4.55% | Sep 2026 |
Top institutions holding KYNB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 400K | 9.88% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 160K | 3.95% | +2.13% | Jun 2026 |
| Acadian Asset Management LLC | 106K | 2.61% | 0.00% | Sep 2026 |
| BlackRock Inc | 84.3K | 2.08% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 43.2K | 1.07% | -6.04% | Jun 2026 |
| HighTower Advisors, LLC | 39.7K | 0.98% | +0.01% | Jun 2026 |
| Two Sigma Investments LLC | 39.5K | 0.98% | -20.20% | Jun 2026 |
| Renaissance Technologies Corp | 35.3K | 0.87% | +30.28% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 24.1K | 0.60% | +0.68% | Jun 2026 |
| Birchview Capital, LP | 22.6K | 0.56% | 0.00% | Jun 2026 |
| State Street Corp | 20.3K | 0.50% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 15.7K | 0.39% | 0.00% | Jun 2026 |
| UBS Group AG | 7.86K | 0.19% | -71.52% | Jun 2026 |
| Group One Trading, LLC | 4.41K | 0.11% | -1.91% | Jun 2026 |
| Vanguard Global Advisers, LLC | 1.42K | 0.04% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.11K | 0.03% | +235.24% | Jun 2026 |
| Axiom Investment Management LLC | 704.00 | 0.02% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 487.00 | 0.01% | -0.20% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 200.00 | 0.00% | 0.00% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 193.00 | 0.00% | 0.00% | Jun 2026 |
Kyntra Bio, Inc. company profile
- Company name
- Kyntra Bio, Inc.
- Ticker
- KYNB.US
- Exchange
- USA Stocks
- Listed since
- Nov 14, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Fiscal year end
- December
- Address
- 350 Bay Street, San Francisco, CA, United States, 94133
- Phone
- 415 978 1200
- Website
- kyntrabio.com
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc. management
7- Mr. Thane WettigCEO & Director · born 1965
- Mr. David DeLuciaSenior VP & CFO · born 1989
- Mr. John AldenCorporate Secretary & General Counsel
- Ms. Michelle SimonettiHead of People and Culture & Executive Director
- Dr. Carrie Brownstein M.D.Chief Medical Officer · born 1970
- Ms. Gaia Vasiliver-ShamisDirector of IR & Communications - LifeSci Advisors
- Ms. Carol GaddumVice President of Product Development